TRANSCRIÇÃO 🔗
0:00
This is an approach that will work. We replace all the damage, all forms of them even de-leverage at once. If you haven't heard of anything yet, the fine conversation might blow your mind and make you think completely differently about aging and what we can do about it. So Shannon is actually way less optimistic about the trajectory of the longevity field than his peers and it's exactly that pessimism that has inspired him to develop a completely different approach and framework to solving aging. These days, John is working on curing brain aging, which I use this word intentionally curing, and in a moment to understand why and how. And we'll keep it quite high level. So if you're interested in more of the details and a roadmap to achieving this, I recommend watching his recent presentation at the Foresight Institute, and I'll share it at the link below. And yeah, that conversation ends a bit differently. It will be followed by a second part. So stay tuned for that and I hope you find John's work as fascinating and as encouraging as I do. You make the distinction between physical aging and biological aging. I've never heard that before. Can you can you clarify what those what they mean and what's the difference? Yeah, for sure. I think it's an important difference because we ignore the physical chemical process of aging, thinking that everything is biological and we can fix everything from a biological, metabolic or enzymatic angle. So we know that there is physical chemical damage that accumulates with age in people over time. It's remarkably linear and it occurs from the time we're made as a fetus or newborn. And this these forms of damage occur in long live proteins, some of which don't turn over at all for our lives, some of which turn over slowly, and then once they accumulate, damage, is no longer turned over. So keep accumulating damage as well. And those are what we would call non enzymatic forms of damage. So it's not something that was generated by a normal process in the body and it's not one that can be reversed by an enzyme or a normal process in the body. And that form of damage is sort of what we see when we see an old person and they're lost all their elasticity and that's not just skin level. That's like all our organs, including our brain, that that is degrading at that level. And no matter what we do to the cells to make them perform better or even transiently and get measures of health that seem to be improved, we have impacted that slow degradation of the long term components of our body. And if we don't do that, we're still going to hit that precipice at about 9100. If you're a real outlier, more 110 years old, but you will hit that precipice and things will precipitously go downhill at that point because your cells just cannot be happy in an environment where the everything is falling apart, the structure, the signals, you know, So so that's that's what I mean by distinction between the the physical chemical process of aging that is not biologic useful. And that's something that is not neglected by all, but but by most people looking to extend life in the longevity space. So this physical chemical damage, it only happens outside of cells, correct? It mostly happens outside of cells. There are some forms of damage to long live protein components that are intracellular DNA is a good example. So in non dividing cells, DNA is there for our entire life. It accumulates mutations that are, you know, not regulated processes, not biologically regulated processes. And there's no way of reversing those either. And so that may also contribute to aging, although I think it's really mostly what's out of cells, some would argue that DNA damage is a central driver of aging. I think over time it can be it certainly is a driver of cancer with age, which is not good. But but, you know, so so yeah, there is some damage that accumulates inside of cells as well. So if I understand correctly, you're saying that most of the work today has to do with the cells while you think that a bigger portion of the damage and that what causes aging is actually the other kind of damage, the damage that happens outside of the cells that is under worked and underappreciated? Yeah, exactly. I think most of the damage occurs outside of cells. It's something that is not easy to measure in the first place. And but thankfully, some biochemists who are interested also in extending life a long time ago studied these forms of damage to our long live proteins and sort of catalog them. And there's no dispute that they they occur they abandon the idea of beating aging because they thought there's no way we can address this this kind of damage. I disagree. I think there is a way and I think we'll get to that shortly. But yeah, that's that's the damage that is neglected. When the focus is on cell processes. You can you can improve a cells process processes as you know, as much as you want, but it is intimately in communication with its environment and that determines ultimately its function, its ability to survive and and lifespan. It's interesting, I heard you say that there is a lot of evidence showing that if you put young cells in an older tissue, they will behave as old cells. And it also works vice versa. Which yes. That it makes sense what you say that, but this is the central problem. Like the more the bigger problem. And can you explain why it's impossible to fix that kind of damage to the audience? If you can? I mean, theoretically, it might be fixable. It's just the we haven't imagined how we might do that yet because of the complexity there. We would need like hundreds of drugs that specifically target these changes in proteins that we don't want with age, these physical chemical changes that occur without affecting, you know, the normal covalent bonds or protein associations that we wouldn't call aggregates, but would call, you know, hetero dimers and multi-year and and and, you know, drugs that
Load full transcript
can fix breaks. That's actually hard to imagine that can ever occur. And, you know, breaks occur in proteins like elastic ends and collisions. So these so, you know, it's just hard to conceive how you could come up with these drugs that might be able to address some of this damage without causing more problems to the functioning of cells by, you know, because drugs always have side effects, even the best ones we have. And so now we're talking about, you know, orders of magnitude more complexity and necessity for specific targeting. Right. Also, genes. You know, a lot of people are using genes or epigenetic approaches like partial reprograming. And you know, that cannot work either because in our genomes we don't have encoded genes that can produce machinery that recognizes this damage or much less can, you know, reverse it or deal with it. So then we're talking about inventing new genetic programs in our cells and delivering them to our cells. And so this is starting to get like, you know, in the realm of hard to imagine how that's going to work sooner than, say, a more straightforward approach of replacing tissues. So just to understand, because we all we've all heard people, some Harvard professors, talk about how we will be able to double our lifespan, live to 200. What what is going on is that are we in denial? Are people in the longevity field actually worried about this aspect? Like how how do people who champion these more mainstream ways of working on it, how do do they view this problem and how do you explain the passivity? Yeah, I mean, I, I know it's difficult for people who have and don't have much of a bio background to appreciate the, you know, all the the the raw data from the literature and look it up and understand it and digest it. So it makes sense that, you know, you would depend in that case on the opinion of experts. So you know, why do certain scientists who you would think would know better sort of either are not aware of this, you know, these types of damage, this physical damage that occurs over time or are ignoring it, knowing that it exists to me is puzzling. I mean, I don't have a good answer. Okay. I really want to hear about the approach you suggest, but just beforehand, with the current approaches that are more common, what do you see as the best case scenario for working on aging? How far can we get. With the current approaches? Yes. Yeah, I don't I don't think we get past the precipice when you know, all of your extra cellular material is degraded. So much that you essentially have, you know, very little homeostasis left, You know, when you're elderly, a mild or a minor infection or, you know, you fall, you break your hip. I mean, that could spell the end. And so we're all still going to hit that point if we're using non replacement approaches to to reverse the damage to not just the cells, but more importantly to the whole tissue with the extracellular component being considered. Would it help, though, compress
morbidity and reduce suffering from age related diseases? Is that kind of the extent of what it can do? Maybe it can. So, you know, I guess I would refer to that as increasing average lifespan or compressing morbidity. Exactly. And so there are already, you know, effective medicine for that that increase health or likelihood of survival. But that's that's essentially what, you know, all of the medical field has been doing up to now is in compressing morbidity for all of us. So some of these approaches could add to that potentially, although none of them have shown great success in doing so yet. But, you know, there is that potential to do so. And where did the idea of using replacement for aging come from? It came from reading the literature. You know, I read a book a long time ago by Caleb Finch of longevity, senescence and the genome or something like that. It's pretty old book, but it had lots of good references, lots of good background. So I started looking up some of these references because I've always been interested in reading aging, you know, ever since I was a kid. And, you know, there were anecdotal, this accumulates with aging. You know, maybe if we target this, we can live longer. And, you know, then one thing after another and there, you know, no one ever seemed to get anywhere. And then, you know, this book led me to all these studies that show this non biological damage that accumulates. I'm like, okay, this is a problem. Like, how could we possibly deal with this? And so, you know, that's what led to the idea that we're going to have to replace not just cells, but tissues. So we need to replace tissues because as as as we said, cells themselves, they are influenced by their environment and we can't just fix the cells. Yeah, Yeah. And you come from a background of genetics, which makes it especially interesting how you kind of like changed our focus to replacement. So if you can explain a bit more about the process you went through, realizing that this was a more effective way to go about things as your interest is in aging. Yeah, exactly. So I've always been interested in beating aging and, you know, at a young age or in even in high school, I was doing a lot of reading on molecular genetics and genetics. And that, you know, DNA is the code of life. How could it not have the answer that we're looking for? And then also did a Ph.D. in genetics at that point. But but already realizing maybe the limitations of genetics. So my Ph.D. was working with embryonic stem cells because of their tremendous potential to to generate all the cell types of the body and even make new bodies new new individuals from from these cells. So that transition was already happening at that point. And then I went on to focus on the part of the body that I would argue is the most important, the brain and the part of the brain that you, you know, defines us as individuals The most might be the neocortex, although it's certainly not the only part of the brain
that does that. Other parts are important as well. So yeah, so that's sort of my journey to get to this point. I heard you say that actually in terms of the FDA, the kind of work that you want to do is much easier actually to get approved because it's nothing new in that sense, as opposed to some like more benign looking, you know, aging drugs that need a much more complicated past approval by the FDA. So in the eyes of the FDA, you're actually more conservative in a way than other approaches. Yeah. And I don't necessarily think the FDA is conservative. I think they're you know, they try to be reasonable. They've made mistakes in the past for sure. And their motives have been in, you know, a minority of cases, misguided in it. But but overall, you know, they they do try to do things the best way they can based on the science and, you know, so for a lot of these drugs that people complain about, you know, we don't not getting FDA approval is because I agree with the FDA. The evidence is just not very good to getting them approved for for these, you know, to for the purpose of reversing aging. Some some of these drugs are very effective for certain conditions, health conditions. And they're used for that. They're approved for that. But, yeah, no, again, you know, replacement being old school approach that has been effective, I think of heart replacements, you know, whether they're artificial hearts or biological hearts, you have a heart that's failing and you have a good heart and you replace it. You know, you're fixed, I mean, to some extent. And you were asking also the question of how you go about dealing with people that think this is a very radical approach. But, you know, in part because it involves surgery, but surgery is like the oldest, most effective medical treatment that we've been using. You know, and to this day, it's probably still one of the most effective approaches to medicine in terms of removing things you don't want or adding missing things, you know, is not great with, you know, bacterial and viral infections. But otherwise it's it's it's an effective tool for lots of ailments, including for the brain. You know, brain surgeries occur, you know, every day and all medical centers around the world. So, you know, it's not really radical. And some individuals have multiple brain surgeries, for example, with tumors that recur or with intractable epilepsy. So, you know, these are almost standard approaches. They're not really radical. They're like old school or anything. But, you know, for progressive brain tissue replacement, which you would need to do in order to maintain cells, now you're, you know, upping the degree of difficulty for sure and upping the risk of complications. And that's something we can't ignore. So this is not something that has been all worked out already. So there's a lot of work ahead, but it is not something that is, you know, sort of unimaginable or that we don't have the at least the technical basis for that We need to improve upon and optimize for our purposes. So can you explain what it means to do replacement when it comes to the brain? And what are the challenges? The challenges come from maintaining self-identity and doing it in a way that doesn't disrupt function, and we have the evidence that this should be doable. So we know that we can. So there's two parts to replacement. One is removing all tissue and then adding new tissue. So we have evidence in the clinic that you can remove old tissue without a loss of function or continuity of function or discontinuity of function. And that comes from different types of lesion. But best studied ones are from slow growing benign gliomas that, unlike Glioblastomas, can be removed once they become a problem. And we've seen those occur, for example, in the language center, in the language center or personality center, and sometimes they'll be monitored for a few years. Sometimes they go undetected for years until a patient has a seizure or really bad headaches. They have an MRI and it's like, you have this massive tumor that's eaten away your language center or, you know, your your frontal lobes, your personality center. And this is an individual's, you know, in their 50 or 6070s. And there's absolutely no change to them, their personality or their language that anyone is detected. And then the surgeon says, you know, we should remove this, go in and take it out. Now they have a big hole where their personnel, much of their personality is to be or a big hole where their language used to be and they're still the same person, or they can still speak in a way that is indistinguishable to how they used to be able to speak. And, you know, despite having a hole where their language center used to be. And that's because those functions over time have moved to a different place. So the timing is one of the challenges here that we're faced with because this level of plasticity is not instantaneous. So if you have a stroke here or a stroke in your language center, those functions are gone. You know, a stroke in your frontal lobes just completely changes your personality and that's it. Or in the language center, same thing. You lose the ability to speak might be a little bit of compensation over time, regaining some words, but it's essentially permanent damage. So plasticity takes time and use so the reason why the language wasn't lost on these patients or their personnel change is because those are things that were used every day by the patients. And so they simply, over time get re encoded into a different part of the cortex. So that's the first part is these clinical examples show that you can lose or remove tissue without a discontinuity of self or personality or function. The other part of the equation is adding new tissue. And here there's a lot of challenge, even more challenge. I think. So adding new tissue is there's good evidence from a good many labs showing that if you put young pre brain precursor
cells in the old brain, they'll follow their normal developmental program, differentiate and connect with appropriate parts of the brain that they would normally, if they're in the visual cortex, for example, they'll connect to visual brain targets. If they're in the actual motor cortex, if they're in the visual cortex, they'll connect to the visual parts of the brain. So they extend and make connections that are appropriate for where you put them in. So that's a really good sign. We and a few other labs have also shown that if you put them in the visual cortex, they also receive inputs from parts of the brain in the sense that over time these new neurons will respond to light, which is also a good sign, so they can connect with the host's brain and they can receive signals from the host brain that appear to be appropriate. But we're still far from being able to achieve tissue replacement because those initial good findings are not functioning. So just having neurons fire appropriately, connect appropriately, respond appropriately is is not equivalent to encoding useful information and processing it in a useful way to the host. We know that for that to happen, you need the normal complexity of the brain tissue to be there and just putting in a bunch of cells does not recapitulate that normal structure and internal connectivity within the graft. And so that's where there's a lot of work to be done, even though there is some proof of principle that if we do it right, connections will be made appropriately with the host brain and you will be able to use that new tissue to encode information in a meaningful way. So that's, you know, that's something that we're working on in my group and I hope more people will work on. Again, we're focusing on one part of the brain, the neocortex, but there are other parts that are important that I hope more people will start working on. So so there's a lot of work ahead. But in principle, this is an approach that will work. You know, we replace all the damage, all forms of them, even DNA damage at once. So we we could really completely reverse aging with replacing old tissue with me to do. This is so interesting how when things happen progressively, then you don't lose the functions because they migrate to other areas. What happens in those areas? Don't they take over other functions that we need? Yeah, I think I think that does happen. I think there's a limited capacity, you know, for encoding information in our brains. It's a very competitive space. You know, what doesn't get used gets lost. You can see that when you look at how elderly, you know, healthy elderly that are for their age, you know, cognitively sharp, they use greater and greater areas of neocortex for their routine daily functions that they think about every day, whereas younger people have much more compartmentalized functions. And so they're older people, even if they appear to be, you know, cognitively sharp, they are doing it at the expense of real estate in their ability to encode broader, you know, cognitive functions and information. So, you know, as you get older, you're you're literally running out of substrate to be functional. But but it's amazing that plasticity it's another great example of plasticity making the most of what substrate it has. It's just the nature of how the neocortex encodes information is very use dependent and very plastic that way. And the challenges you described in the work in replacing brain tissue, what makes you more optimistic about those challenges than about challenges such as just fixing, fixing tissue, not by replacement? Yeah, so that's a great question. So, you know, the fixing tissues that as we described at the outset has as the need for inventing a lot of new things, new technologies of the replacement approach is one that, you know, we don't really have to invent anything new. I mean, we didn't make the brains in our heads, you know, it it was made we have the blueprint of how it was made during development. We know if we do a high enough resolution analysis of the cell types and the extracellular environment of those cells by proteomics, we can get a very clear blueprint that already exists of what we need to achieve to recapitulate that developmental process in adult post brain. So this does not sound like fantasy, this just sounds like hard work. We need to advertise this and make it work. After that, it's, you know, it's surgery. And again, you know, there are risks or complications that we can try to minimize, but it's not you know, surgery is not something that we have to invent. It's not a new technology. Although, you know, again, I think that's something that we want to minimize the risk of complications from surgery. And so improving that is also an area that I think is very important to pursue. How would it work at scale? How many surgeons will we need to have trained to do surgeries to, like all people are getting older all day long? Yeah, Yeah. I mean, there's the scaling there, there's the surgical approach, but there's also the source of the replacement tissue. If it's if it's an engineered approach from IPS cells where we make a fetal or an embryonic light precursor tissue that we've shown works after grafting that can be scaled up, as you know, at again, not, not, not the easiest thing to scale, but there are already people working on this. There are already people scaling IPS cells or you simpler versions of a replacement where it's just focused on the cells or just focused on like extracellular matrices. Those are already being scaled. So putting them together will require a little more engineering, but nothing new in terms of technological inventions. So I think the if that's the source of tissue that we end up using, I think we can scale that there are other potential sources as well. So, you know, some people are working on these synthetic embryos or taking IPS cells and instead of making the different brain precursor
cell types, you just develop a synthetic embryo to a stage that's old enough that it has the brain tissue you want for grafting. And, you know, I assume that can be scaled as well. Is it these these are growing in bioreactors, so just more bioreactors, more of those. And of course, reproducibility is is is a must, or at least if not a must, then you have to be able to identify, you know, the the ones that grew the way you wanted to that you can use as a source tissue. You should be able to scale that as well in the past we've used fetal cells for to treat brain diseases like Parkinson's. That's much harder to scale and much, much harder to control reproducibility, which is why, you know, most places stop using these fetal cells, even though they've showed that in some cases they essentially cured the Parkinson's patients. But because of the lack of reproducibility in the source of cells, in some cases that made the patients worse. So so they stopped using those. But I was wondering about that. Yeah. Yeah. And how do you imagine let's just talk about the brain it playing out, let's say we're in a world where this technology exists, so at what age would around what age would a person start getting surgeries and gradually replacing their brain tissue? And how long would it take and how many surgeries would it be? I think ideally, you know, there are factors that are going to impact the choice of age of onset for these, as well as how many surgeries you'll want to do. You also asked about the scaling of surgeries, which is something that I think is a good question as well. But we can you know, maybe I can quickly address that here. But, you know, it would take it would take a lot of training. But again, you know, you can set up programs to do that. There's a lot of ways you can train surgeons in these approaches. And, you know, we can definitely push for that. There's also, you know, the smart surgical robots are getting better and better. And so that and I assume they'll they'll just get a lot better in the next ten years as well. So that's another avenue for scaling the surgical part. So the the onset of treatment would depend on how the rate at which you're currently losing your cognitive functions like how much every year is it worth it to you compared to the where the risk of complications is at at the time this technology is developed? If the risk of complications is really low, you might be fine starting, you know, in your fifties, sixties, seventies. You know, it might be a matter of choice. If the risk of complications is still somewhat high, you might want to wait seventies eighties to start doing this. So I think that's going to be the balance. And the number of surgeries also might depend to some extent on, you know, how what age you are when you start these, you know, if you're starting later in your eighties nineties, you know you might want to sort of an accelerated version of this treatment whereas if you're starting younger and you're fifties sixties you know you might take the more conservative approach that would involve, you know, maybe you know, a dozen surgeries over the course of, you know, two or three decades. Okay. So you decided to focus on your brain because I get the impression that when it comes to the body and are different ways to go about it, that seems like an easier problem. But can you kind of give an overview of what it would entail and what approaches? Right now what you're thinking of is optional? Yeah. So there's progress being made on and I guess two broad different fronts. One is biological replacement and one is non-biological replacement. And they can both be broken down into like whole body replacement, either synthetic or biological or, you know, more part by part replacement. So that's roughly the approaches that are being taken for the synthetic replacement of whole body. For example, there's a group at Yale that's developing technology that's of interest. This is not a systems group where they can keep brains at least metabolically alive for for quite sometime, not long enough to be of interest yet. But, you know, it's technology that's developing, but it's completely synthetic way of keeping brains alive. With that, of course, you'd have to incorporate more, you know, brain machine interfaces so that you could actually interact with the world. But those are also being developed separately by other companies. There's also biological replacement, which is more intuitive. You know, we know new bodies live, you know, 80, 90, but, you know, 100 years. And so, you know, we already have a proof of concept for biological bodies. And those can also be produced right now only with, you know, foster mothers that would be willing to produce these bodies. But also, you know, they would have to be produced in a way that's ethical so that, you know, there is no sentient being that that's in these bodies. So these are these would be brainless or headless bodies that that would be developed. This would be likely to be highly controversial. But it is a you know, technologically speaking, a way that could be used to replace the whole body. And then there's more part by part approaches where, you know, you can think of the synthetic heart as an example versus, you know, a donor heart or a heart grown in another species. Those are already being done today. So that's not that futuristic. You know, it does. Those technologies are implemented today and of course, for long term use would probably need to be optimized. But broadly speaking, those are the approaches one can conceive of for for the body.